Dr. Burtness on Findings of KEYNOTE-048 in Head and Neck Cancer

Dr. Burtness on Findings of KEYNOTE-048 in Head and Neck Cancer  OncLiveImmunotherapy improves survival in metastatic or recurrent head and neck cancer  EurekAlert (press release)First-line pembrolizumab a new standard for recurrent, metastatic head and neck squamous cell carcinoma  HealioFull coverage

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2DoT5g0